| 000 | 01873 a2200505 4500 | ||
|---|---|---|---|
| 005 | 20250515174246.0 | ||
| 264 | 0 | _c20100511 | |
| 008 | 201005s 0 0 eng d | ||
| 022 | _a1473-5571 | ||
| 024 | 7 |
_a10.1097/QAD.0b013e328327964f _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aGolub, Jonathan E | |
| 245 | 0 | 0 |
_aIsoniazid preventive therapy, HAART and tuberculosis risk in HIV-infected adults in South Africa: a prospective cohort. _h[electronic resource] |
| 260 |
_bAIDS (London, England) _cMar 2009 |
||
| 300 |
_a631-6 p. _bdigital |
||
| 500 | _aPublication Type: Controlled Clinical Trial; Journal Article; Multicenter Study; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S. | ||
| 650 | 0 | 4 |
_aAIDS-Related Opportunistic Infections _xepidemiology |
| 650 | 0 | 4 | _aAdult |
| 650 | 0 | 4 |
_aAnti-HIV Agents _xtherapeutic use |
| 650 | 0 | 4 | _aAntiretroviral Therapy, Highly Active |
| 650 | 0 | 4 |
_aAntitubercular Agents _xtherapeutic use |
| 650 | 0 | 4 | _aCD4 Lymphocyte Count |
| 650 | 0 | 4 | _aEpidemiologic Methods |
| 650 | 0 | 4 | _aFemale |
| 650 | 0 | 4 |
_aHIV Infections _xdrug therapy |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 |
_aIsoniazid _xtherapeutic use |
| 650 | 0 | 4 | _aMale |
| 650 | 0 | 4 | _aMiddle Aged |
| 650 | 0 | 4 | _aSex Factors |
| 650 | 0 | 4 |
_aSouth Africa _xepidemiology |
| 650 | 0 | 4 | _aTreatment Outcome |
| 650 | 0 | 4 |
_aTuberculosis _xepidemiology |
| 700 | 1 | _aPronyk, Paul | |
| 700 | 1 | _aMohapi, Lerato | |
| 700 | 1 | _aThsabangu, Nkeko | |
| 700 | 1 | _aMoshabela, Mosa | |
| 700 | 1 | _aStruthers, Helen | |
| 700 | 1 | _aGray, Glenda E | |
| 700 | 1 | _aMcIntyre, James A | |
| 700 | 1 | _aChaisson, Richard E | |
| 700 | 1 | _aMartinson, Neil A | |
| 773 | 0 |
_tAIDS (London, England) _gvol. 23 _gno. 5 _gp. 631-6 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1097/QAD.0b013e328327964f _zAvailable from publisher's website |
| 999 |
_c18944909 _d18944909 |
||